Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risperdal and Prozac are among top five subjects of adverse event reports to FDA in 1995.

Executive Summary

JANSSEN RISPERDAL ACCOUNTS FOR 2% OF POST-MARKETING ADE REPORTS to FDA, according to the agency's 1995 Annual Adverse Drug Experience Report released in late January by the Division of Pharmacovigilance and Epidemiology. The agency received 2,540 adverse event reports for Risperdal (risperidone) out of a total of 130,950 ADEs reported during 1995, making the antipsychotic the fifth most frequently mentioned "suspect" drug in the database.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel